Allspring Global Investments Holdings, LLC Kiniksa Pharmaceuticals, Ltd. Transaction History

Allspring Global Investments Holdings, LLC

$62.1 Billion
Q3 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 18, 2024	BUY	$17.63 - $21.74 $167,308 - $206,312	9,490 Added 18.39%	61,106 $1.21 Million
Q4 2023 Jan 25, 2024	SELL	$14.37 - $19.07 $142,492 - $189,098	-9,916 Reduced 16.12%	51,616 $905,000
Q3 2023 Oct 27, 2023	BUY	$13.62 - $20.2 $838,065 - $1.24 Million	61,532 New	61,532 $1.07 Million
Q2 2023 Jul 18, 2023	BUY	$10.44 - $16.48 $2.29 Million - $3.61 Million	219,302 Added 148.51%	366,975 $5.17 Million
Q1 2023 Apr 13, 2023	SELL	$10.7 - $15.79 $721,672 - $1.06 Million	-67,446 Reduced 31.35%	147,673 $1.59 Million
Q4 2022 Jan 23, 2023	BUY	$11.42 - $17.05 $2.21 Million - $3.3 Million	193,404 Added 890.65%	215,119 $0
Q3 2022 Oct 26, 2022	BUY	$9.76 - $13.41 $771 - $1,059	79 Added 0.37%	21,715 $278,000
Q2 2022 Jul 25, 2022	SELL	$7.6 - $11.41 $1,687 - $2,533	-222 Reduced 1.02%	21,636 $209,000
Q1 2022 May 02, 2022	SELL	$9.3 - $12.37 $2,492 - $3,315	-268 Reduced 1.21%	21,858 $217,000
Q4 2021 Jan 28, 2022	BUY	$10.39 - $15.15 $229,889 - $335,208	22,126 New	22,126 $260,000

Others Institutions Holding KNSA

# of Institutions

Shares Held

1.95M

Call Options Held

Put Options Held

Pictet Asset Management Sa Geneva 73, V8

1.52M
Shares

$30.2 Million
0.03% of portfolio
Spearhead Capital Advisors, LLC Wellington, FL

203K
Shares

$4.04 Million
2.82% of portfolio
Harbor Capital Advisors, Inc.

98.1K
Shares

$1.95 Million
0.08% of portfolio
Putnam Investments LLC Boston, MA

39.5K
Shares

$786,955
0.0% of portfolio
Birchview Capital, LP Burlington, VT

30K
Shares

$597,900
0.69% of portfolio

View Full List

About Kiniksa Pharmaceuticals, Ltd.

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $687M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

More about KNSA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Allspring Global Investments Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Allspring Global Investments Holdings, LLC with notifications on news.

Account